A Phase 1 dose-ranging study examining the effects of a superabsorbent polymer (CLP) on fluid sodium and potassium excretion in healthy subjects

摘要

BackgroundCLP is an orally administered, non-absorbed, superabsorbent polymer being developed to increase fecal excretion of sodium, potassium and water in patients with heart failure and end-stage renal disease. This study was conducted to evaluate the safety of CLP, and to explore dose-related effects on fecal weight, fecal and urine sodium and potassium excretion, and serum electrolyte concentrations.